| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 1 day from now) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 1 day from now) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(1 year, 1 day from now) | |
Prialt is owned by Tersera.
Prialt contains Ziconotide Acetate.
Prialt has a total of 3 drug patents out of which 0 drug patents have expired.
Prialt was authorised for market use on 28 December, 2004.
Prialt is available in injectable;intrathecal dosage forms.
Prialt can be used as analgesia; treatment of pain, treatment of pain; analgesia, treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine.
The generics of Prialt are possible to be released after 01 October, 2024.
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Analgesia; Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine
Dosage: INJECTABLE;INTRATHECAL
PRIALT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic